Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept

被引：7
|
作者：
Otten, Marieke H. [1 ]
Prince, Femke H. M. [1 ]
Twilt, Marinka [2 ]
van Rossum, Marion A. J. [3 ]
Armbrust, Wineke [4 ]
Hoppenreijs, Esther P. A. H. [5 ]
Kamphuis, Sylvia [1 ]
Koopman-Keemink, Yvonne [6 ]
Wulffraat, Nico M. [7 ]
Gorter, Simone L. [8 ]
ten Cate, Rebecca [2 ]
van Suijlekom-Smit, Lisette W. A. [1 ]
机构：
[1] Erasmus MC, Sophia Childrens Hosp, Dept Paediat, NL-3000 CB Rotterdam, Netherlands
[2] Leiden Univ, Med Ctr, Dept Paediat, Leiden, Netherlands
[3] Emma Childrens Hosp, Acad Med Ctr, Jan van Breemen Inst, Dept Paediat, Amsterdam, Netherlands
[4] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Paediat, NL-9713 AV Groningen, Netherlands
[5] Radboud Univ Nijmegen, Med Ctr, Dept Paediat, NL-6525 ED Nijmegen, Netherlands
[6] Hagaziekenhuis Juliana Childrens Hosp, Dept Paediat, The Hague, Netherlands
[7] Utrecht MC Wilhelmina Childrens Hosp, Dept Paediat, Utrecht, Netherlands
[8] Univ Limburg, Acad Hosp Maastricht, Dept Internal Med, Rheumatol Subdiv, Maastricht, Netherlands
来源：
JOURNAL OF RHEUMATOLOGY | 2010年 / 37卷 / 03期
关键词：
JUVENILE IDIOPATHIC ARTHRITIS; ANTIRHEUMATIC AGENTS; TUMOR NECROSIS FACTOR-alpha; DRUG ADMINISTRATION SCHEDULE; TREATMENT OUTCOME; ARTHRITIS; RHEUMATOID-ARTHRITIS; EFFICACY; CHILDREN; THERAPY; SAFETY;
D O I：
10.3899/jrheum.090550
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Objective. To evaluate response in patients with juvenile idiopathic arthritis (JIA) who failed to meet response criteria after 3 months of etanercept treatment. Methods. This was a prospective ongoing Multicenter observational study of all Dutch patients with JIA using etanercept. Response according to American College of Rheumatology Pediatric 30 criteria was assessed at study start and at 3 and 15 months. Results. In total we studied 179 patients of median age 5.8 years at disease onset; 70% were female. Thirty-four patients did not respond after 3 months, of which 20 continued etanercept and 11 achieved response thereafter. Conclusion. The delayed clinically relevant response in a substantial proportion of patients who initially did not respond justifies the consideration of continuing therapy to at least 6 months. (First Release Jan 15 2010; J Rheumatol 20 10;37:665-7 doi: 10.3899/jrheum.090550)
引用
收藏
页码：665 / 667
页数：3
相关论文
共 50 条
  • [1] Etanercept treatment for children with refractory juvenile idiopathic arthritis
    Kuo, Ho-Chang
    Yu, Hong-Ren
    Wu, Chih-Chiang
    Chang, Ling-Sai
    Yang, Kuender D.
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2011, 44 (01) : 52 - 56
  • [2] Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis
    Geikowski, Tilman
    Becker, Ingrid
    Horneff, Gerd
    RHEUMATOLOGY, 2014, 53 (07) : 1245 - 1249
  • [3] Efficacy of etanercept in the treatment of juvenile idiopathic arthritis
    de Inocencio Arocena, J.
    Merino Munoz, R.
    Alvarez Madrid, C.
    Garcia-Consuegra Molina, J.
    ANALES DE PEDIATRIA, 2009, 70 (04): : 354 - 361
  • [4] Factors Associated With Treatment Response to Etanercept in Juvenile Idiopathic Arthritis
    Otten, Marieke H.
    Prince, Femke H. M.
    Armbrust, Wineke
    ten Cate, Rebecca
    Hoppenreijs, Esther P. A. H.
    Twilt, Marinka
    Koopman-Keemink, Yvonne
    Gorter, Simone L.
    Dolman, Koert M.
    Swart, Joost F.
    van den Berg, J. Merlijn
    Wulffraat, Nico M.
    van Rossum, Marion A. J.
    van Suijlekom-Smit, Lisette W. A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (21): : 2340 - 2347
  • [5] Development of Inflammatory Bowel Disease in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept
    van Dijken, Trudy D.
    Vastert, Sebastiaan J.
    Gerloni, Valeria M.
    Pontikaki, Irene
    Linnemann, Kristina
    Girschick, Hermann
    Armbrust, Wineke
    Minden, Kirsten
    Prince, Femke H. M.
    Kokke, Freddy T. M.
    Nieuwenhuis, Edward E. S.
    Horneff, Gerd
    Wulffraat, Nico M.
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (07) : 1441 - 1446
  • [6] Herpes Virus Infections During Treatment With Etanercept in Juvenile Idiopathic Arthritis
    Nicolai, R.
    Cortis, E.
    Rava, L.
    Bracaglia, C.
    Pardeo, M.
    Insalaco, A.
    Buonuomo, P. S.
    Tozzi, A. E.
    De Benedetti, F.
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2016, 5 (01) : 76 - 79
  • [7] Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients
    Southwood, Taunton R.
    Foster, Helen E.
    Davidson, Joyce E.
    Hyrich, Kimme L.
    Cotter, Catherine B.
    Wedderburn, Lucy R.
    Hull, Richard G.
    Venning, Helen E.
    Rahman, Joy K.
    Cummins, Carole L.
    RHEUMATOLOGY, 2011, 50 (01) : 189 - 195
  • [8] Early Prediction of Clinical Response to Etanercept Treatment in Juvenile Idiopathic Arthritis Using Machine Learning
    Mo, Xiaolan
    Chen, Xiujuan
    Leong, Chifong
    Zhang, Song
    Li, Huiyi
    Li, Jiali
    Lin, Guohao
    Sun, Guangchao
    He, Fan
    He, Yanling
    Xie, Ying
    Zeng, Ping
    Chen, Yilu
    Liang, Huiying
    Zeng, Huasong
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [9] Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab
    Horneff, Gerd
    Klein, Ariane
    Klotsche, Jens
    Minden, Kirsten
    Huppertz, Hans-Iko
    Weller-Heinemann, Frank
    Kuemmerle-Deschner, Jasmin
    Haas, Johannes-Peter
    Hospach, Anton
    ARTHRITIS RESEARCH & THERAPY, 2016, 18
  • [10] Clinical trial of etanercept tapering in juvenile idiopathic arthritis during remission
    Cai, Yubo
    Liu, Xiaosheng
    Zhang, Wenming
    Xu, Jianrong
    Cao, Lanfang
    RHEUMATOLOGY INTERNATIONAL, 2013, 33 (09) : 2277 - 2282
12345